To validate our model of therapy-induced senescence (TIS), we firstly quantified the cytostatic effect of the CDK4/6 inhibitor palbociclib by analyzing the cell cycle of human breast cancer cells following palbociclib treatment. The gene discussed is CDK4; the disease is breast carcinoma.